Please login to the form below

Wilmington Healthcare appoints new Account Director

Healthcare intelligence provider Wilmington Healthcare, which incorporates Binley’s, NHiS, Wellards and HSJ, has strengthened its salesforce with the appointment of Gareth Thurston as Account Director.

In his new post, Gareth will be overseeing a number of key accounts across the Wilmington Healthcare portfolio and ensuring that the relevant specialist teams meet their objectives.

Gareth who has worked in sales and marketing roles in the healthcare industry for nearly 30 years, joins Wilmington Healthcare from Cello Health Consulting Ltd, where he was a consultant.

Prior to that, Gareth spent nearly 10 years at Novartis Pharmaceuticals UK Limited, where he held a number of different roles, including Marketing Manager and Franchise Lead for the company’s transplantation portfolio. His final post at the company was Brand Lead, Ophthalmology.   Before joining Novartis, Gareth held senior sales and product manager positions at Gilead Sciences Ltd in their anti-infective franchise.

Gareth Thomas, Managing Director of Wilmington Healthcare, said: “Having worked in sales and marketing roles in the healthcare industry for nearly 30 years, Gareth Thurston brings a wealth of experience to his new job.

“He will play an important role in supporting our clients to achieve greater success, whilst helping our business to continue to go from strength to strength. We are very pleased to welcome him to our team.” 


Gareth Thurston

26th September 2017

Share

Tags

Company Details

Wilmington Healthcare

01268 495600

Contact Website

Address:
Beechwood House
2-3 Commercial Way
Christy Close
Southfields
Basildon
SS15 6EF
United Kingdom

Latest content on this profile

MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE
With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is it responding to this challenge, and what can industry do to support it? Oli Hudson, Content Director at Wilmington Healthcare, explains what’s changing and how industry should respond.
Wilmington Healthcare
ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS
With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes and why they matter for pharma and med-tech companies.
Wilmington Healthcare
HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW
Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to the NHS and its prescribing behaviours during the peak of the pandemic.  Oli Hudson summarises five of the key findings:
Wilmington Healthcare
ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.
Wilmington Healthcare
Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed

Wilmington Healthcare
EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES
As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its part.
Wilmington Healthcare